NCT06210971View on ClinicalTrials.gov

Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

July 1, 2028

Conditions
Rectal Cancer
Interventions
DRUG

liposomal irinotecan

Liposomal irinotecan: 50mg/m\^2 or 70mg/m\^2

DRUG

Capecitabine

Capecitabine: 625mg/m\^2 or 1000mg/m\^2 bid.

RADIATION

Radiation threapy

50.4Gy/28 fractions

Trial Locations (1)

050000

RECRUITING

Hebei Medical University Fourth Hospital, Shijiazhuang

All Listed Sponsors
lead

Hebei Medical University Fourth Hospital

OTHER